How is Hemophilia Considered a Genetic Disorder?

1
Hemophilia A - Pipeline Review, H2 2015
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Hemophilia A Pipeline Review, H2 2015, provides
  an overview of the Hemophilia As therapeutic
  pipeline.
• This report provides comprehensive information on
  the therapeutic development for Hemophilia A,
  complete with comparative analysis at various
  stages, therapeutics assessment by drug target,
  mechanism of action (MoA), route of
  administration (RoA) and molecule type, along
  with latest updates, and featured news and press
  releases. It also reviews key players involved in
  the therapeutic development for Hemophilia A and
  special features on late-stage and discontinued
  projects.
• The report features investigational drugs from
  across globe covering over 20 therapy areas and
  nearly 3,000 indications. The report is built
  using data and information sourced from Global
  Markets Directs proprietary databases,
  Company/University websites, SEC filings,
  investor presentations and featured press
  releases from company/university sites and
  industry-specific third party sources, put
  together by Global Markets Directs team. Drug
  profiles/records featured in the report undergoes
  periodic updation following a stringent set of
  processes that ensures that all the profiles are
  updated with the latest set of information.
  Additionally, processes including live news
  deals tracking, browser based alert-box and
  clinical trials registries tracking ensure that
  the most recent developments are captured on a
  real time basis.
• The report enhances decision making capabilities
  and help to create effective counter strategies
  to gain competitive advantage. It strengthens RD
  pipelines by identifying new targets and MOAs to
  produce first-in-class and best-in-class
  products.
• Strategic Focus Report http//www.researchbeam.co
  m/hemophilia-a-pipeline-review-h2-2015-market

3


Report Overview

• Scope
• The report provides a snapshot of the global
  therapeutic landscape of Hemophilia A
• The report reviews key pipeline products under
  drug profile section which includes, product
  description, MoA and RD brief, licensing and
  collaboration details other developmental
  activities
• The report reviews key players involved in the
  therapeutics development for Hemophilia A and
  enlists all their major and minor projects
• The report summarizes all the dormant and
  discontinued pipeline projects
• A review of the Hemophilia A products under
  development by companies and universities/research
  institutes based on information derived from
  company and industry-specific sources
• Reasons to buy
• Provides strategically significant competitor
  information, analysis, and insights to formulate
  effective RD development strategies
• Identify emerging players with potentially strong
  product portfolio and create effective
  counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding
  the focus areas of leading companies
• Identify and understand important and diverse
  types of therapeutics under development for
  Hemophilia A
• Plan mergers and acquisitions effectively by
  identifying key players of the most promising
  pipeline

4


Table of Contents
List of Tables 4 List of Figures 6 Introduction
7 Global Markets Direct Report Coverage
7 Hemophilia A Overview 8 Therapeutics
Development 9 Pipeline Products for Hemophilia A
- Overview 9 Pipeline Products for Hemophilia A -
Comparative Analysis 10 Hemophilia A -
Therapeutics under Development by Companies
11 Hemophilia A - Therapeutics under
Investigation by Universities/Institutes
15 Hemophilia A - Pipeline Products Glance
16 Late Stage Products 16 Clinical Stage Products
17 Early Stage Products 18 Unknown Stage Products
19 Hemophilia A - Products under Development by
Companies 20 Hemophilia A - Products under
Investigation by Universities/Institutes
23 Hemophilia A - Companies Involved in
Therapeutics Development 24 Alnylam
Pharmaceuticals, Inc. 24 Amarna Therapeutics B.V.
25 Apitope International NV 26 AstraZeneca Plc
27 Baxalta Incorporated 28
5


Report Ordering
Report Name Hemophilia A - Pipeline
Review, H2 2015
Product Price
User Price
Single User US 1700
Site User US 4000
Global User US 6000
To View Sample or Purchase Report
6



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/hemophilia-a-pipeline-
review-h2-2015-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com